DE602006015338D1 - CHOLINERGE ENHANCER WITH IMPROVED THROUGHOUT THE BLOOD-BRAIN DISEASE FOR THE TREATMENT OF DISEASES THAT COMBINE WITH COGNITIVE INTERFERENCE - Google Patents

CHOLINERGE ENHANCER WITH IMPROVED THROUGHOUT THE BLOOD-BRAIN DISEASE FOR THE TREATMENT OF DISEASES THAT COMBINE WITH COGNITIVE INTERFERENCE

Info

Publication number
DE602006015338D1
DE602006015338D1 DE602006015338T DE602006015338T DE602006015338D1 DE 602006015338 D1 DE602006015338 D1 DE 602006015338D1 DE 602006015338 T DE602006015338 T DE 602006015338T DE 602006015338 T DE602006015338 T DE 602006015338T DE 602006015338 D1 DE602006015338 D1 DE 602006015338D1
Authority
DE
Germany
Prior art keywords
cholinerge
enhancer
diseases
combine
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006015338T
Other languages
German (de)
Inventor
Alfred Maelicke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galantos Pharma GmbH
Original Assignee
Galantos Pharma GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05020721A external-priority patent/EP1777222A1/en
Application filed by Galantos Pharma GmbH filed Critical Galantos Pharma GmbH
Publication of DE602006015338D1 publication Critical patent/DE602006015338D1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DE602006015338T 2005-09-22 2006-09-22 CHOLINERGE ENHANCER WITH IMPROVED THROUGHOUT THE BLOOD-BRAIN DISEASE FOR THE TREATMENT OF DISEASES THAT COMBINE WITH COGNITIVE INTERFERENCE Active DE602006015338D1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05020721A EP1777222A1 (en) 2005-09-22 2005-09-22 Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
US78024306P 2006-03-07 2006-03-07
PCT/EP2006/009220 WO2007039138A1 (en) 2005-09-22 2006-09-22 Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment

Publications (1)

Publication Number Publication Date
DE602006015338D1 true DE602006015338D1 (en) 2010-08-19

Family

ID=40506504

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006015338T Active DE602006015338D1 (en) 2005-09-22 2006-09-22 CHOLINERGE ENHANCER WITH IMPROVED THROUGHOUT THE BLOOD-BRAIN DISEASE FOR THE TREATMENT OF DISEASES THAT COMBINE WITH COGNITIVE INTERFERENCE

Country Status (4)

Country Link
JP (1) JP2009508903A (en)
AT (1) ATE473219T1 (en)
CY (1) CY1110822T1 (en)
DE (1) DE602006015338D1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2877165T3 (en) * 2012-07-27 2019-01-02 Neurodyn Life Sciences Inc Improved brain bioavailability of galantamine by selected formulations and transmucosal administration of lipophilic prodrug

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE411026T1 (en) * 1987-05-04 2008-10-15 Bonnie Davis AGENTS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
US6323195B1 (en) * 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
MXPA01012275A (en) * 2000-03-31 2003-06-24 Sanochemia Pharmazeutika Ag Novel derivatives and analogues of galanthamin.
AT414125B (en) * 2003-09-29 2006-09-15 Sanochemia Pharmazeutika Ag NEW DERIVATIVES OF 4A, 5,9,10,11,12-HEXAHYDRO-BENZOFURO (3A, 3,2) (2) BENZAZEPINE, PROCESS FOR THE PRODUCTION THEREOF AND THEIR USE FOR THE PRODUCTION OF MEDICAMENTS

Also Published As

Publication number Publication date
CY1110822T1 (en) 2015-06-10
JP2009508903A (en) 2009-03-05
ATE473219T1 (en) 2010-07-15

Similar Documents

Publication Publication Date Title
DE602006019838D1 (en) PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE FOR THE TREATMENT OF MENTAL DISEASES
ATE429218T1 (en) PINOLENEIC ACID FOR THE TREATMENT OF OBESITY
ATE540941T1 (en) 1-Ä2-(2,4-DIMETHYLPHENYLSULFANYL)PHENYLÜPIPERAZ N AS A COMPOUND WITH COMBINED SEROTONIN REUPPOST, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE DISORDERS
ATE476414T1 (en) BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES
ATE399155T1 (en) IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
ATE424386T1 (en) PYRIDINE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN-MEDIATED DISEASES
DE60303238D1 (en) Pyrimidine-acetic acid derivatives suitable for the treatment of CRTH2-related diseases
ATE527241T1 (en) PYRIDIAZINONE DERIVATIVES FOR THE TREATMENT OF TUMORS
ATE550338T1 (en) SPIROPIPERIDINE INHIBITORS OF BETA-SECRETASE FOR THE TREATMENT OF ALZHEIMER'S DISEASE
DE602006010132D1 (en) Intermediates for the preparation of trans-5-chloro-2-methyl-2,3,3a, 12b-tetrahydro-1h-dibenzE2,3: 6,7O-oxo-amino-4,5-cpyrrole
NL1028599A1 (en) Compounds for the treatment of diseases.
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
ATE482709T1 (en) NEW DRUG COMBINATIONS FOR THE TREATMENT OF RESPIRATORY DISEASES
DE502006008804D1 (en) NEW, LONG-ACTIVE BETAMIMETICS FOR THE TREATMENT OF RESPIRATORY DISEASES
DE602006003094D1 (en) 4-PHENYL-5-OXO-1,4,5,6,7,8-HEXAHYDROCHINOLINE DERIVATIVES FOR THE TREATMENT OF BARRENESS
NL1026203A1 (en) Compounds useful for the treatment of diseases.
ITRM20050179A1 (en) APPLICABLE COMPOSITION FOR THE TREATMENT OF PARADONTAL DISEASES.
ATE443704T1 (en) PYRIDOPYRIMIDINONE FOR THE TREATMENT OF CANCER DISEASES
ATE504297T1 (en) VISNADIN FOR THE TREATMENT OF ITCH OF THE SCALP
ATE517877T1 (en) NEW DRUGS FOR THE TREATMENT OF RESPIRATORY DISEASES
DE602005016141D1 (en) S-MIRTAZAPINE FOR THE TREATMENT OF HITZEWALLUNGEN
DE602006002608D1 (en) 4-PHENYL-5-OXO-L, 4,5,6,7,8-HEXAHYDROCHINOLINE DERIVATIVES AS A MEDICAMENT FOR THE TREATMENT OF BARRENESS
EA200702336A1 (en) APPLICATION 24-NorUDK
DE602005013650D1 (en) PROTEIN HYDROLYSATE FOR THE TREATMENT OF TIREDNESS
DE602005013287D1 (en) COMPOSITION FOR THE TREATMENT OF LEATHER